Spinas GA - Search Results

1

The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.

Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA. Palmer AJ, et al. Among authors: spinas ga. Curr Med Res Opin. 2004 Aug;20 Suppl 1:S5-26. doi: 10.1185/030079904X1980. Curr Med Res Opin. 2004. PMID: 15324513

2

Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom.

Palmer AJ, Roze S, Valentine WJ, Spinas GA, Shaw JE, Zimmet PZ. Palmer AJ, et al. Among authors: spinas ga. Clin Ther. 2004 Feb;26(2):304-21. doi: 10.1016/s0149-2918(04)90029-x. Clin Ther. 2004. PMID: 15038953

3

Validation of the CORE Diabetes Model against epidemiological and clinical studies.

Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA. Palmer AJ, et al. Among authors: spinas ga. Curr Med Res Opin. 2004 Aug;20 Suppl 1:S27-40. doi: 10.1185/030079904X2006. Curr Med Res Opin. 2004. PMID: 15324514

4

Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes.

Palmer AJ, Roze S, Lammert M, Valentine WJ, Minshall ME, Nicklasson L, Gall MA, Spinas GA. Palmer AJ, et al. Among authors: spinas ga. Curr Med Res Opin. 2004 Aug;20 Suppl 1:S41-51. doi: 10.1185/030079904X2015. Curr Med Res Opin. 2004. PMID: 15324515

5

Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model.

Palmer AJ, Roze S, Valentine WJ, Minshall ME, Hayes C, Oglesby A, Spinas GA. Palmer AJ, et al. Among authors: spinas ga. Curr Med Res Opin. 2004 Aug;20 Suppl 1:S53-8. doi: 10.1185/030079903125002611. Curr Med Res Opin. 2004. PMID: 15324516

6

What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model.

Palmer AJ, Roze S, Valentine WJ, Minshall ME, Lammert M, Oglesby A, Hayes C, Spinas GA. Palmer AJ, et al. Among authors: spinas ga. Curr Med Res Opin. 2004 Aug;20 Suppl 1:S59-66. doi: 10.1185/030079904X2024. Curr Med Res Opin. 2004. PMID: 15324517

7

Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy.

Palmer AJ, Roze S, Valentine WJ, Minshall ME, Lammert M, Nicklasson L, Spinas GA. Palmer AJ, et al. Among authors: spinas ga. Curr Med Res Opin. 2004 Aug;20 Suppl 1:S67-73. doi: 10.1185/030079904X2033. Curr Med Res Opin. 2004. PMID: 15324518

8

Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.

Palmer AJ, Roze S, Valentine WJ, Ray JA, Frei A, Burnier M, Hess B, Spinas GA, Brändle M. Palmer AJ, et al. Among authors: spinas ga. Swiss Med Wkly. 2006 May 27;136(21-22):346-52. doi: 10.57187/smw.2006.11337. Swiss Med Wkly. 2006. PMID: 16779715 Free article.

9

Economic and clinical impact of alternative disease management strategies for secondary prevention in type 2 diabetes in the Swiss setting.

Gozzoli V, Palmer AJ, Brandt A, Spinas GA. Gozzoli V, et al. Among authors: spinas ga. Swiss Med Wkly. 2001 Jun 2;131(21-22):303-10. doi: 10.4414/smw.2001.09716. Swiss Med Wkly. 2001. PMID: 11584692 Free article.

10

Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland.

Brändle M, Erny-Albrecht KM, Goodall G, Spinas GA, Streit P, Valentine WJ. Brändle M, et al. Among authors: spinas ga. Int J Clin Pharmacol Ther. 2009 Aug;47(8):501-15. doi: 10.5414/cpp47501. Int J Clin Pharmacol Ther. 2009. PMID: 19640359 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

209 results

Search Page

Filters